Literature DB >> 7911244

Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.

G F Lauritzsen1, S Weiss, Z Dembic, B Bogen.   

Abstract

The immunosurveillance hypothesis suggests that lymphocytes can recognize tumor-specific antigens expressed by transformed cells and initiate their elimination. Immunosurveillance implies that lymphocytes of naive phenotype can home to a tumor site and become activated by tumor-specific antigens. In this study, we have employed T-cell receptor transgenic mice as a source of naive, tumor-specific T cells. The transgenic, CD4+ T cells recognize a 91- to 101-residue fragment of the lambda 2(315) immunoglobulin light chain presented by I-Ed class II molecules. Such naive, idiotype-specific, CD4+ T cells protected against tumor development of a class II negative plasmacytoma (MOPC315) and a class II positive B lymphoma (F9), which both secrete lambda 2(315) immunoglobulin. Adoptive transfer experiments demonstrated that 2 x 10(6) lymph node cells were sufficient for protection against MOPC315. Depletion of T-cell subsets indicated that transgenic CD4+ cells were indispensable for tumor resistance. However, an additional role of CD8+ T cells is not ruled out. In contrast to the resistance against the secreting MOPC315 and F9 cells, transgenic mice were not protected against B lymphoma cells (F67), which do not secrete lambda 2(315) but express a truncated lambda 2(315) chain intracellularly. The results suggest that lambda 2(315) is processed and presented by host antigen-presenting cells, which in turn activate naive, idiotype-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911244      PMCID: PMC44064          DOI: 10.1073/pnas.91.12.5700

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Identification of an alternative CTLA-4 ligand costimulatory for T cell activation.

Authors:  K S Hathcock; G Laszlo; H B Dickler; J Bradshaw; P Linsley; R J Hodes
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

2.  Mouse myeloma proteins with antihapten antibody acitivity. The protein produced by plasma cell tumor MOPC-315.

Authors:  H N Eisen; E S Simms; M Potter
Journal:  Biochemistry       Date:  1968-11       Impact factor: 3.162

3.  Variability in the lambda light chain sequences of mouse antibody.

Authors:  M G Weigert; I M Cesari; S J Yonkovich; M Cohn
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

4.  Antibody responses to lambda 1J558 and lambda 2315 light chains. Specificity and genetic regulation.

Authors:  B Bogen
Journal:  Scand J Immunol       Date:  1984-11       Impact factor: 3.487

Review 5.  Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T cell-mediated cytolysis.

Authors:  M Sarmiento; D P Dialynas; D W Lancki; K A Wall; M I Lorber; M R Loken; F W Fitch
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

6.  Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315.

Authors:  T Jørgensen; G Gaudernack; K Hannestad
Journal:  Scand J Immunol       Date:  1980       Impact factor: 3.487

7.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

Authors:  S Baskar; S Ostrand-Rosenberg; N Nabavi; L M Nadler; G J Freeman; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

8.  Myeloma proteins as tumor-specific transplantation antigens.

Authors:  R G Lynch; R J Graff; S Sirisinha; E S Simms; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

9.  Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells.

Authors:  R Ceredig; J W Lowenthal; M Nabholz; H R MacDonald
Journal:  Nature       Date:  1985 Mar 7-13       Impact factor: 49.962

10.  Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice.

Authors:  S Sugai; D W Palmer; N Talal; I P Witz
Journal:  J Exp Med       Date:  1974-12-01       Impact factor: 14.307

View more
  38 in total

1.  Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis.

Authors:  Elaine J Schattner; Steven M Friedman; Paolo Casali
Journal:  Autoimmunity       Date:  2002-07       Impact factor: 2.815

2.  Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.

Authors:  O A Haabeth; A Tveita; M Fauskanger; K Hennig; P O Hofgaard; B Bogen
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

3.  Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.

Authors:  Z Dembic; K Schenck; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 4.  CD4 T cells in tumor immunity.

Authors:  Mara Gerloni; Maurizio Zanetti
Journal:  Springer Semin Immunopathol       Date:  2005-03-15

Review 5.  Rous-Whipple Award lecture. The biology and pathology of lymphocyte Fc receptors.

Authors:  R G Lynch
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

6.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

Authors:  L W Kwak; H A Young; R W Pennington; S D Weeks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.

Authors:  Sungyoul Hong; Jianfei Qian; Jing Yang; Haiyan Li; Larry W Kwak; Qing Yi
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

8.  Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.

Authors:  John M Timmerman; Julie M Vose; Debra K Czerwinski; Wen-Kai Weng; Diane Ingolia; Martha Mayo; Dan W Denney; Ronald Levy
Journal:  Leuk Lymphoma       Date:  2009-01

9.  Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen.

Authors:  Elena Shklovskaya; Alexandra M Terry; Thomas V Guy; Adrian Buckley; Holly A Bolton; Erhua Zhu; Jeff Holst; Barbara Fazekas de St. Groth
Journal:  Immunol Cell Biol       Date:  2016-02-03       Impact factor: 5.126

10.  CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.

Authors:  Ole Audun W Haabeth; Kjartan Hennig; Marte Fauskanger; Geir Åge Løset; Bjarne Bogen; Anders Tveita
Journal:  Blood Adv       Date:  2020-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.